IAP
ZYME icon

Indie Asset Partners’s Zymeworks ZYME Stock Holding History

Indie Asset Partners’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,450
Closed -$224K – 132
2021
Q2 		$224K Hold
6,450
– – 0.18% 113
2021
Q1 		$204K Buy
+6,450
New +$262K 0.23% 114

Other funds holding ZYME

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Indie Asset Partners's ZYME Position: Q3 2021 in Review

Indie Asset Partners sold out of Zymeworks (ZYME) in Q3 2021, closing a stake of 6,450 shares — an estimated $224K sold.

Indie Asset Partners first reported a position in ZYME in Q1 2021 and held it in 2 quarters. The position peaked at $224K in Q2 2021. 123 funds tracked by Wall St. Rank hold ZYME as of Q3 2021.

  • Indie Asset Partners reported no remaining Zymeworks position as of Q3 2021 after selling out during the quarter.
  • Indie Asset Partners sold 6,450 Zymeworks shares in Q3 2021, an estimated $224K.
  • Indie Asset Partners first reported a position in Zymeworks in Q1 2021 and held it in 2 quarters.
  • Indie Asset Partners's Zymeworks position peaked at $224K in Q2 2021.
  • 123 funds tracked by Wall St. Rank held Zymeworks as of Q3 2021.

Based on Indie Asset Partners's 13F filing for Q3 2021, filed 9 Nov 2021.